Targeted sequencing reveals the relationship between mutations and patients’ clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma

Abstract

In the current study, we assessed the relationship between mutations and the blood cell counts and early progression of patients with diffuse large-B cell lymphoma (DLBCL). A total of 109 patients with newly diagnosed DLBCL were included in this study. UBE2A mutation was only found in patients with bone marrow involvement. The mutations of ZNF608, SF3B1, DTX1, and NCOR2 were related to blood cell counts. NCOR2 mutations were only detected in patients of the noncomplete response group (PR + SD + PD). In addition, the mutations of ATM, BTG2, TBL1XR1, and TP53 were linked to lower PFS/OS rate, while SGK1, SCOS1, and NFKBIE were related to higher PFS/OS rate. Importantly, we identified that Ann Arbor stage (III–IV), B symptoms, absolute lymphocyte count (ALC) abnormity, and MTOR mutation were the four independent influencing factors of the 12-month progression of DLBCL patients. Overall, this study revealed that mutations were associated with the early progression of DLBCL.

Keywords:

• Mutation
• blood cell counts
• response to therapy
• prognosis
• early progression
• diffuse large-B cell lymphoma

Acknowledgements

We thank Shanghai Rightongene Biotechnology Co. Ltd (Shanghai, China) for the bioinformatics analysis.

Ethical approval

This study was performed in compliance with the Declaration of Helsinki, and approved by the Ethic Committee of the Fourth Hospital of Hebei Medical University.

Consent form

Informed consent was obtained from all individual participants included in the study.

Author contributions

GMZ and GYM designed the study. GYM, YHG, XTJ, CYH, HSL, XLW, ZG, YL, and SNZ provided the study material or patients in this study. GYM and YHG collected the data and performed the statistical data analysis. GMZ drafted and revised the manuscript. All authors contributed to the development of the manuscript and approved the final version.

Disclosure statement

The authors declare no conflict of interest.

Data availability statement

The data used to support the finding of this study may be released upon application to the corresponding author.

Additional information

Funding

This study was funded by the Beijing-Tianjin-Hebei Basic Research Cooperation Project (No. H2018206591).